EGFR and non-small cell lung carcinoma: In summary, our prospective, randomized, open-label, national multi-center phase III clinical study demonstrated that single-agent SCA has similar ORR and DCR and PFS and OS benefits to single-agent DOX in the second-line treatment of advanced/metastatic NSCLC with wild-type or unknown EGFR status, with a lower risk of hepatotoxicity/gastrointestinal toxicity and better QoL.